期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺癌靶向治疗研究进展 被引量：3

下载PDF
导出
摘要 目的对国内外肺癌靶向治疗相关研究进行总结。方法以"肺癌"及"靶向治疗"为关键词,在CNKI及PUBMDE期刊中检索近10年来的中文及英文文献资料。以表皮生长因子受体酪氨酸激酶抑制剂、以肿瘤血管生成为靶点的治疗以及多靶点治疗在肺癌中的作用为标准,针对24篇文章进行分析。结果在表皮生长因子受体酪氨酸激酶抑制剂领域的研究相对成熟,特别是吉非替尼,相关临床治疗实验表明,对吉非替尼二线治疗效果方面发挥决定性影响的可能是EGFR突变;在以肿瘤血管生成为靶点的治疗上,对于复发NSCLC患者而言,贝伐单抗与化疗联合使用与化疗单独使用相比,前者对于PFSD的提升效果更为明显;在晚期NSCLC治疗中,血管内皮抑素Ⅲ期实验表明,血管内皮抑素与NP联合使用域NP单独使用相比,前者有效率明显高于后者。结论肺癌靶向治疗相关研究进展较快,具有极为广阔的应用前景,为肺癌治疗开辟新思路。
作者 董耀众
机构地区 烟台毓璜顶医院
出处 《中外医疗》 2012年第9期189-189,共1页 China & Foreign Medical Treatment
关键词 肺癌 靶向治疗 研究进展
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献30

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量：625
  • 2Fukuoka M,Yano S, Giaccone G, et al. Multi institutionalran- domized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer(The IDEAL 1 Trial) [J]. J Clin Oncol,2003,21(12) :2237-2246.
  • 3Kris M G,Natale R B, Herbst R S, et ah Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase.in symptomatic patients with non-small-cell lung cancer: a randomized trial[J]. JAMA,2003,290(16) :2149-2158.
  • 4Chang A, Parikh P, Thongprasers, et al. Gefitinib(IRESSA)in patients of asian origin with rrefractory advanced non-small cell lung cancer:subset analysis from the ISEL study[J]. Throac On col, 2006,1 (8) : 847-885.
  • 5Giaceone G, Herbst R S, Manegold C, et al. Gefitinib incombination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III triaI-INTACTI [J].J Clin Oncol, 2004,22 (5):777-784.
  • 6Herbst R S, Giaccone G, Schiller J H, et al. Gefitinibincombi nation with paclitaxel and carboplatin in advanced non small cell lung cancer: a phase III trial-INTACT2[J]. J Clin Oncol,2004, 22(5) :785-794.
  • 7Kim E S, Hirsh V, Mok T, et al. Gefitinib versus docetaxelin previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial1 [J ]. Lancet, 2008,372 (9652) 1809- 1818.
  • 8Tony S. Mok, Yi-Long Wu, F. A. C. S. ,et al. Gefitinib or Carboplatin paclitaxel in pulmonary adenocarcinoma[J].The New England Journal of Medicine, 2009, 361(10): 947-957.
  • 9Shepherd F A, Rodrigues-Pereira J, Ciuleanu T, et al. Erlotinib inp reviously treated non-small-cell lung cancer[J]. N Engl J Med, 2005, 353(2): 123-132.
  • 10Zhu C Q, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in national cancer institute of canada clinical trials group study BR. 21[J].J Clin Oncol, 2008,26(26) :4268-4275.

共引文献17

同被引文献43

  • 1Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in2008:GLOBOCAN2008[J].Int J Cancer,2010,127(12):2893.
  • 2Cappuzzo F,Hirsch FR,Rossi E,et al.Epidermal grow-th factor receptor gene and protein and gefitinib sensitivi-ty in non-small-cell lung cancer[J].J Nat Cancer Insti-tute,2005,97(9):643.
  • 3Vincent MD,Kuruvilla MS,Leighl NB,et al.Biomark-ers that currently affect clinical practice:EGFR,ALK,MET,KRAS[J].Cur Oncol,2012,19(Suppl1):S33.
  • 4Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J].Nature,2007,448(7153):561.
  • 5Sasaki T,Rodig SJ,Chirieac LR,et al.The biology and treatment of EML4-ALK non-small cell lung cancer[J].Eur J Cancer,2010,46(10):1773.
  • 6Bang YJ.The potential for crizotinib in non-small cell lu-ng cancer:a perspective review[J].Therap Advances MedOncol,2011,3(6):279.
  • 7Ou SH.Crizotinib:a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond[J].Drug Design Dev Therapy,2011(5):471.
  • 8Natale RB,Bodkin D,Govindan R,et al.Vandetan-ib versus gefitinib in patients with advanced non-small-ce-ll lung cancer:results from a two-part,double-blind,ran-domized phaseⅡstudy[J].J Clin Oncol,2009,27(15):2523.
  • 9Stmo L Songg Z, zhang y, et al. Advances of molecular subtype and targeted titerapy of lmgeaaeer [J]. ghongguo Fei Ai Za Zhi, 2012, 15 (9): 545-552.
  • 10Mollberg N, Surati M,. Demchuk C,. et al. Mind -mapping for lung cancer: towards: a personalized therapeutics approach [ J ]. Adv Ther, 2011, 28 (3):: 173-194.

引证文献3

二级引证文献14

中外医疗
2012年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部